Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 29;13(17):2797.
doi: 10.3390/diagnostics13172797.

Precision Medicine in Inflammatory Bowel Disease

Affiliations
Review

Precision Medicine in Inflammatory Bowel Disease

Vito Annese et al. Diagnostics (Basel). .

Abstract

Ulcerative colitis and Crohn's disease are traditionally defined as the two main subtypes of inflammatory bowel disease. However, a more recent view considers IBD as a spectrum of heterogeneous phenotypes with consistent differences in clinical presentation and behaviors, likely explained by differences in underlying pathogenetic mechanisms. The etiology is still elusive, and the suggested pathogenesis is a complex interplay among genetic predisposition and abnormal immune response at the mucosal intestinal level, activated by only partially identified environmental triggers leading to altered intestinal permeability and impaired handling of gut microbiota. The undeniable continuous progress of medical therapy with more frequent shifts from traditional to more advanced modalities also underlines the actual unmet needs. We are using medications with completely different mechanisms of action, with a lack of predictive factors of outcomes and response and still an unsatisfactory rate of success. In addition, we are missing still valuable and accurate markers to predict disease progression and severity in order to avoid under- or over-treatment. In such a complex scenario, it is undoubtful that the application of artificial intelligence and machine learning algorithms may improve the management and pave the way for precision and eventually personalized medicine in these patients; however, there are still several challenges that will be the focus of this review.

Keywords: Crohn’s disease (CD); artificial intelligence (AI); inflammatory bowel disease (IBD); precision medicine (PM); ulcerative colitis (UC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An example of the potential of the evaluation by system biology of multi-omics in IBD aiming to achieve with more “precision” a tailored therapy and better outcomes.
Figure 2
Figure 2
A graphic scheme of the multi-step process of analysis starting from patient’s biosamples; the combination of clinical data and multi-omics results in artificial neural networks will progressively elaborate the large complexity and number of data to deliver hopefully more individualized and precise output.

References

    1. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based study. Lancet. 2018;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
    1. Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1. - DOI - PubMed
    1. Ungaro R., Mehandru S., Allen P.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi: 10.1016/S0140-6736(16)32126-2. - DOI - PMC - PubMed
    1. Borg-Bartolo S.P., Boyapati R.K., Satsangi J., Kalla R. Precision medicine in inflammatory bowel disease: Concept, progress and challenges. FI000Research. 2020;9 doi: 10.12688/f1000research.20928.1. - DOI - PMC - PubMed
    1. Verstockt B., Noor N.M., Marigorta U.M., Pavlidis P., Deepak P., Ungaro R.C., Scientific Workshop Steering Committee Results of the 7th Scientific Workshop of ECCO: Precision Medicine in IBD—Disease outcome and response to therapy. J. Crohn’s Colitis. 2021;15:1431–1442. doi: 10.1093/ecco-jcc/jjab050. - DOI - PMC - PubMed

LinkOut - more resources